Dirui Industrial Co (300396) Q3 2026 earnings summary

Executive summary

• Q3 revenue was ¥221.95m, up 88.00% YoY; YTD revenue reached ¥630.48m, up 34.50%, driven mainly by domestic growth.

• YTD net loss attributable to shareholders was ¥15.62m, versus ¥87.25m in the prior-year period; impairment charges and higher finance costs weighed on results.

• Excluding impairment and other cited impacts, Q3 performance improved; management cited adequate funding and stronger receivables collection.

Financial highlights

• Q3 net loss attributable to shareholders was ¥23.22m; adjusted net loss was ¥24.63m.

• YTD adjusted net loss was ¥24.24m; YTD net loss attributable to shareholders was ¥15.62m.

• YTD operating cash flow was negative ¥127.46m, versus negative ¥58.21m in the prior-year period; refunds of previously received contract payments were a key driver.

• YTD revenue increased ¥161.73m YoY; total assets were ¥2.46bn, down 11.20% from year-end.

Outlook and guidance

• Priorities include advancing high-end instruments in benchmark hospitals and tier-three hospitals, and building reagent revenue following international installations.

• Management plans to deepen finance-operations integration, intelligent seal controls and full-lifecycle contract management to reinforce remediation and efficiency.